Compare Incyte Corporation (INCY) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oklo Inc — how do they compare? Incyte Corporation trades at $117.54 (market cap $23.11B), while Oklo Inc trades at $43.62 (market cap $7.22B). The key difference: Incyte Corporation is far larger — about 3.2× Oklo Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| INCY | OKLO | |
|---|---|---|
Market Cap | $23.11B | $7.22B |
Sector | Health | Technology |
52-Week High | $118.52 | $174.14 |
52-Week Low | $67.38 | $41.11 |
Enterprise Value | $19.13B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
OKLO trades at $41.51, down 42% year-to-date amid regulatory uncertainty and recent stock dilution. The company shows strong analyst support with 77% buy ratings and a $90.88 consensus price target, but fundamentals remain weak with negative earnings and cash flow. Recent news highlights progress on nuclear projects but regulatory hurdles persist.
OKLO presents high-risk/high-reward potential with significant upside to analyst targets but faces execution risks and negative profitability. The stock's bearish technical signals contrast with bullish long-term nuclear energy thesis. Regulatory approvals and Meta partnership execution remain critical catalysts for valuation recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
